Neuromuscular blocking agents in the intensive care unit: a two-edged sword.
Sladen
R N
RN
D003362:Cost-Benefit Analysis; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects; D008991:Monitoring, Physiologic; D009123:Muscle Hypotonia / Q000517:prevention & control; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects; D010243:Paralysis / Q000517:prevention & control
D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D003473:Neuromuscular Nondepolarizing Agents; C049429:doxacurium